ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Division Spotlight
Decommissioning & Environmental Sciences
The mission of the Decommissioning and Environmental Sciences (DES) Division is to promote the development and use of those skills and technologies associated with the use of nuclear energy and the optimal management and stewardship of the environment, sustainable development, decommissioning, remediation, reutilization, and long-term surveillance and maintenance of nuclear-related installations, and sites. The target audience for this effort is the membership of the Division, the Society, and the public at large.
Meeting Spotlight
2024 ANS Winter Conference and Expo
November 17–21, 2024
Orlando, FL|Renaissance Orlando at SeaWorld
Standards Program
The Standards Committee is responsible for the development and maintenance of voluntary consensus standards that address the design, analysis, and operation of components, systems, and facilities related to the application of nuclear science and technology. Find out What’s New, check out the Standards Store, or Get Involved today!
Latest Magazine Issues
Aug 2024
Jan 2024
Latest Journal Issues
Nuclear Science and Engineering
October 2024
Nuclear Technology
Fusion Science and Technology
August 2024
Latest News
New laws offer nuclear industry incentives for existing power plant uprates
This year, the U.S. nuclear industry received a much-needed economic boost that could help preserve operating nuclear power plants and incentivize upgrades that extend their lifespan and power output.
Signed into law in 2022, the Inflation Reduction Act offers production tax credits (PTCs) for existing nuclear power plants and either PTCs or investment tax credits (ITCs) for new carbon-free generation. These credits could make power uprates—increasing the maximum power level at which a commercial plant may operate—a much more appealing option for utilities.
Francisco J. Souto, Robert H. Kimpland, A. Sharif Heger
Nuclear Science and Engineering | Volume 150 | Number 3 | July 2005 | Pages 322-335
Technical Paper | doi.org/10.13182/NSE05-A2519
Articles are hosted by Taylor and Francis Online.
One of the primary methods to produce medical isotopes, such as 99Mo, is by irradiation of uranium targets in heterogeneous reactors. Solution reactors present a potential alternative to produce medical isotopes. The Medical Isotope Production Reactor (MIPR) concept has been proposed to produce medical isotopes with lower uranium consumption and waste than those in heterogeneous reactors. Commercial production of medical isotopes in solution reactors requires steady-state operation at ~200 kW. At this power regime, fuel-solution temperature increase and radiolytic-gas bubble formation introduce a negative reactivity feedback that has to be mitigated. A model based on the point reactor kinetic equations has been developed to investigate these reactivity effects. This model has been validated against experimental results from the Los Alamos National Laboratory uranyl fluoride Solution High-Energy Burst Assembly (SHEBA) and shows the feasibility of solution reactors for the commercial production of medical isotopes.